Overview

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Status:
Recruiting
Trial end date:
2025-04-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company